Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Myeloid 1

Conditions

Myelodysplastic Syndromes 54Leukemia, Myeloid, Acute 53Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Myeloproliferative Disorders 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Non-Hodgkin 19Leukemia, Myelomonocytic, Chronic 16Primary Myelofibrosis 13Leukemia 11Hodgkin Disease 11Sarcoma 9Polycythemia Vera 9Neuroblastoma 9Histiocytosis, Langerhans-Cell 9Glioma 9Wilms Tumor 8Rhabdoid Tumor 8Neuroectodermal Tumors, Primitive, Peripheral 8Medulloblastoma 8Leukemia, Biphenotypic, Acute 8Hepatoblastoma 8Ependymoma 8Anemia, Refractory, with Excess of Blasts 8Thrombocythemia, Essential 7Rhabdomyosarcoma 7Osteosarcoma 7Myelodysplastic-Myeloproliferative Diseases 7Blast Crisis 7Multiple Myeloma 6Blastic Plasmacytoid Dendritic Cell Neoplasm 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immune System Diseases × Myeloid × 30 days × Clear all
NCT05186753 2026-05-22

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

Cogent Biosciences, Inc.

Phase 2 Active not recruiting
237 enrolled
Myeloid

Hematologic Diseases, Hypersensitivity, Immune Complex Diseases, Immune System Diseases, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡